4.1 Review

Neurodegeneration in multiple sclerosis: novel treatment strategies

Journal

EXPERT REVIEW OF NEUROTHERAPEUTICS
Volume 12, Issue 9, Pages 1061-1076

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.12.59

Keywords

multiple sclerosis; neurodegeneration; neuronal injury; neuroprotection; treatment

Funding

  1. Teva
  2. Novartis
  3. Merck Serona
  4. Bayer
  5. Johnson Johnson
  6. Ono
  7. Octapharma

Ask authors/readers for more resources

In recent years it has become clear that the neuronal compartment already plays an important role early in the pathology of multiple sclerosis (MS). Neuronal injury in the course of chronic neuroinflammation is a key factor in determining long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has major implications for therapy, with CNS protection and repair needed in addition to controlling inflammation. Here, the authors' review recently elucidated molecular insights into inflammatory neuronal/axonal pathology in MS and discuss the resulting options regarding neuroprotective and regenerative treatment strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available